The next generation immune checkpoint inhibitors and stimulators market is projected to grow at an annualized rate of ~10.5%(RootsAnalysis)
Roots Analysis has done a detailedstudy on Peptidesand Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030, covering keyaspects of the industry’s evolution and identifying potential future growthopportunities.
To order this 180+page report, which features 90+ figures and 85+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle-discovery/300.html
Key Market Insights
§ More than 35 industryplayers claim to offer services for the identification, characterization anddevelopment of peptides and macrocycle-based pharmacological lead candidates
§ Several technologydevelopers have made significant contributions in terms of developing novelplatforms, based on a variety of innovative approaches, for the discovery ofpeptide-based drugs and macrocyclic molecules.
§ Service providers areexpanding their capabilities in order to enhance their respective portfolios;display libraries have emerged the most popular platforms.
§ In recent years, asteady increase in partnership activity has been observed, resulting in theestablishment of a variety of deals related to different types of peptides andmacrocycles.
§ Drug developers are likely to continue to outsource discovery stage operationsfor therapeutic peptides and macrocyclic drugs in mid to long term, resultingin multi-billion growth for contract service providers.
§ Given the recentdevelopments in healthcare, supporting safety and efficacy of peptide andaffiliated macrocycle drugs, the industry is presently witnessing an increasein discovery and development initiatives related to such therapeuticmodalities.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle-discovery/300.html
Table of Contents
1. PREFACE
1.1. Scope ofthe Report
1.2. Research Methodology
1.3. ChapterOutlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1. ChapterOverview
3.2. History ofPeptide Drugs
3.3. Structureof Peptides
3.4. MajorClasses of Peptides
3.5. DiscoveryStages of Peptides
3.6. Synthesisof Peptides
3.7. Modificationof Peptides
3.8. Methods forPeptide Analysis
3.9. ContractResearch Organizations (CROs) in Peptides and Macrocycle Drug Discovery
3.10. Key Factorsin CRO Selection
3.11. Risks andChallenges Associates with CROs
4. MARKETLANDSCAPE OF SERVICE PROVIDERS
4.1. ChapterOverview
4.2. Peptidesand Macrocycle Drug Discovery Service Providers: Overall Market Landscape
4.2.1. Analysis byYear of Establishment
4.2.2. Analysis byCompany Size
4.2.3. Analysis byLocation of Headquarters
4.2.4. Analysis byDrug Discovery Steps
4.2.5. Analysis byType of Peptides Discovered
4.2.6. Analysis byPeptide Generation Methods Used
4.2.7. Analysis byPeptide Modification Methods Used
4.2.8. Analysis byOther Services Offered
5. BENCHMARKANALYSIS
5.1. ChapterOverview
5.2. Methodology
5.3. Region-wiseBenchmarking
5.3.1. Europe,Peer Group I
5.3.2. NorthAmerica, Peer Group II
5.3.3. AsiaPacific, Peer Group III
5.4. Summary ofRegion-wise Benchmarking Analysis
5.5. CompanySize-wise Benchmarking
5.5.1. Companies inDifferent Peer Groups
5.5.2. SmallCompanies, Peer Group I
5.5.3. Mid-SizedCompanies, Peer Group II
5.5.4. Large andVery Large Companies, Peer Group III
5.6. Summary of Company-Sizewise Benchmarking Analysis
6. MARKETLANDSCAPE OF PLATFORM PROVIDERS
6.1. ChapterOverview
6.2. Peptidesand Macrocycle Drug Discovery Platform Providers: Overall Market Landscape
6.2.1. Analysis byYear of Establishment
6.2.2. Analysis byCompany Size
6.2.3. Analysis byLocation of Headquarters
6.2.4. Analysis byType of Peptides Discovered
6.3. 2X2 Matrix
6.3.1. SectionOverview
6.3.2. 2X2 Matrix:An Overview
6.3.3. Methodologyand Scoring
6.3.4. 2X2 Matrix:Plotting the Information
6.3.5. 2X2 Matrix:Analyzing the Information
6.3.5.1. High / HighCompartment
6.3.5.2. Low / HighCompartment
7. COMPANYPROFILES
7.1. ChapterOverview
7.2. Peptidesand Macrocycle Drug Discovery Service Providers
7.2.1. GenScript
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.3. Future Outlook
7.2.2. JPT PeptideTechnologies
7. 2.2.1. Company Overview
7. 2.2.2. Service Portfolio
7. 2.2.3. Future Outlook
7.2.3. IRBM
7.2.3.1. Company Overview
7.2.3.2. ServicePortfolio
7.2.3.3. Future Outlook
7.2.4. Pepscan
7.2.4.1. Company Overview
7.2.4.2. Service Portfolio
7.2.4.3. Future Outlook
7.3 Peptidesand Macrocycle Drug Discovery Platform Providers
7.3.1. Interprotein
7.3.1.1. Company Overview
7.3.1.2. Technology Overview
7.3.1.3. Future Outlook
7.3.2. RAPharmaceuticals
7. 3.2.1. Company Overview
7. 3.2.2. Technology Overview
7. 3.2.3. Future Outlook
7.3.3. Pepticom
7.3.3.1. Company Overview
7.3.3.2. TechnologyOverview
7.3.3.3. Future Outlook
7.3.4. PeptiDream
7.3.4.1. Company Overview
7.3.4.2. Technology Overview
7.3.4.3. Financial Information
7.3.4.4. FutureOutlook
7.3.5. CreativeBiolabs
7.3.5.1. Company Overview
7.3.5.2. Service Portfolio
7.3.5.3. TechnologyOverview
7.3.5.4. Future Outlook
7.3.6. MeSCue-Janusys
7.3.6.1. Company Overview
7.3.6.2. Peptide Discovery Platform
7.3.6.3. Future Outlook
7.3.7. CycleniumPharma
7.3.7.1. Company Overview
7.3.7.2. Technology Overview
7.3.7.3. Future Outlook
7.3.8. OrbitDiscovery
7.3.8.1. Company Overview
7.3.8.2. Technology Overview
7.3.8.3. Future Outlook
8. PARTNERSHIPS
8.1. ChapterOverview
8.2. PartnershipModels
8.3. Peptidesand Macrocycle Drug Discovery Services and Platforms Providers: List ofPartnerships
8.3.1. Analysis byYear of Partnerships
8.3.2. Analysis byType of Partnerships
8.3.3. Analysis byYear and Type of Partnerships
8.3.4. Analysis byType of Peptides
8.3.5. Analysis byKey Focus Areas
8.4. GeographicalAnalysis
8.4.1. Local andInternational Agreements
8.4.2. Intercontinentaland Intracontinental Agreements
8.5. Most ActivePlayers: Analysis by Number of Partnerships
9. MARKETFORECAST AND OPPORTUNITY ANALYSIS
9.1. ChapterOverview
9.2. KeyAssumptions and Forecast Methodology
9.3. OverallPeptide Drug Discovery Outsourcing Services Market, 2020-2030
9.4. PeptideDrug Discovery Outsourcing Services Market: Analysis by Type of Peptide, 2020,2025 and 2030
9.4.1. Peptide DrugDiscovery Outsourcing Services Market for Synthetic Peptides, 2020-2030
9.4.2. Peptide DrugDiscovery Outsourcing Services Market for Biological Peptides, 2020-2030
9.5. PeptideDrug Discovery Outsourcing Services Market: Analysis by Drug Discovery Steps,2020, 2025 and 2030
9.5.1. Peptide DrugDiscovery Outsourcing Services Market for Target Validation, 2020-2030
9.5.2. Peptide DrugDiscovery Outsourcing Services Market for Hit Identification, 2020-2030
9.5.3. Peptide DrugDiscovery Outsourcing Services Market for Lead Generation, 2020-2030
9.5.4. Peptide DrugDiscovery Outsourcing Services Market for Lead Optimization, 2020-2030
9.6. PeptideDrug Discovery Outsourcing Services Market: Analysis by Therapeutic Area, 2020,2025 and 2030
9.6.1. Peptide DrugDiscovery Outsourcing Services Market for Oncological Disorders, 2020-2030
9.6.2. Peptide DrugDiscovery Outsourcing Services Market for Metabolic Disorders, 2020-2030
9.6.3. Peptide DrugDiscovery Outsourcing Services Market for Cardiovascular Disorders, 2020-2030
9.6.4. Peptide DrugDiscovery Outsourcing Services Market for Neurological Disorders, 2020-2030
9.6.5. Peptide DrugDiscovery Outsourcing Services Market for Genetic Disorders, 2020-2030
9.6.6. Peptide DrugDiscovery Outsourcing Services Market for Gastroenterological Disorders,2020-2030
9.6.7. Peptide DrugDiscovery Outsourcing Services Market for Gynecological Disorders, 2020-2030
9.6.8. PeptideDrug Discovery Outsourcing Services Market for Hematological Disorders,2020-2030
9.6.9. Peptide Drug Discovery Outsourcing ServicesMarket for Ophthalmological Disorders, 2020-2030
9.6.10. Peptide DrugDiscovery Outsourcing Services Market for Endocrine Disorders, 2020-2030
9.6.11. Peptide DrugDiscovery Outsourcing Services Market for Infectious Diseases, 2020-2030
9.6.12. Peptide DrugDiscovery Outsourcing Services Market for Other Diseases, 2020-2030
9.7. PeptideDrug Discovery Outsourcing Services Market: Analysis by Company Size, 2020,2025 and 2030
9.7.1. Peptide DrugDiscovery Outsourcing Services Market for Small Companies, 2020-2030
9.7.2. Peptide DrugDiscovery Outsourcing Services Market for Mid-Sized Companies, 2020-2030
9.7.3. Peptide DrugDiscovery Outsourcing Services Market for Large Companies, 2020-2030
9.8. PeptideDrug Discovery Outsourcing Services Market: Analysis by Geography, 2020-2030
9.8.1. PeptideDrug Discovery Outsourcing Services Market in North America, 2020-2030
9.8.2. PeptideDrug Discovery Outsourcing Services Market in Europe, 2020-2030
9.8.3. PeptideDrug Discovery Outsourcing Services Market in Asia Pacific, 2020-2030
9.8.4. Peptide Drug Discovery Outsourcing ServicesMarket in Rest of the World, 2020-2030
10. SWOTANALYSIS
10.1. ChapterOverview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
10.6. ConcludingRemarks
11. CONCLUSION
11.1. ChapterOverview
11.2. KeyTakeaways
12. EXECUTIVEINSIGHTS
12.1. ChapterOverview
12.2 CycleniumPharma
12.2.1. CompanySnapshot
12.2.2. Mark LPeterson (Chief Operating Officer, Cyclenium Pharma)
12.3. Oncodesign
12.3.1. CompanySnapshot
12.2.2. Jan Hoflack(Chief Scientific Officer, Head of Biotech Business Unit, Oncodesign)
13. APPENDIX 1:LIST OF COMPANIES AND ORGANIZATIONS
14. APPENDIX 2:TABULATED DATA
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
